Docoh
Loading...

ABT Abbott Laboratories

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Its portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.

Company profile

Ticker
ABT
Exchange
Website
CEO
Robert Ford
Employees
Incorporated
Location
Fiscal year end
SEC CIK
Subsidiaries
Abbott Biologicals, LLC • Abbott Cardiovascular Inc. • Abbott Cardiovascular Systems Inc. • Abbott Delaware LLC • Abbott Diabetes Care Inc. • Abbott Diabetes Care Sales Corporation • Abbott Diagnostics Scarborough, Inc. • Abbott Equity Investments LLC • Abbott Finance LLC • Abbott Global LLC ...
IRS number
360698440

ABT stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

4 Aug 21
23 Sep 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
8 Sep 21 Michael J Pederson Common shares without par value Sell Dispose S No No 129.0496 23,008 2.97M 62,571
8 Sep 21 Michael J Pederson Common shares without par value Option exercise Acquire M No No 50.72 23,008 1.17M 85,579
8 Sep 21 Michael J Pederson Option Common Shares Option exercise Dispose M No No 50.72 23,008 1.17M 0
3 Sep 21 Randel William Woodgrift Common shares without par value Sell Dispose S No No 129 5,350 690.15K 43,743
3 Sep 21 Randel William Woodgrift Common shares without par value Sell Dispose S No No 129 1,000 129K 49,093
3 Sep 21 Randel William Woodgrift Common shares without par value Option exercise Acquire M No No 38.4 1,000 38.4K 50,093
3 Sep 21 Randel William Woodgrift Option Common Shares Option exercise Dispose M No No 38.4 1,000 38.4K 1,333
2 Sep 21 Andrea F Wainer Common shares without par value Sell Dispose S No No 127.5 9,500 1.21M 49,782
2 Sep 21 Andrea F Wainer Common shares without par value Option exercise Acquire M No No 38.4 5,000 192K 59,282
2 Sep 21 Andrea F Wainer Common shares without par value Option exercise Acquire M No No 47 4,500 211.5K 54,282

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

72.4% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 2425 2446 -0.9%
Opened positions 126 158 -20.3%
Closed positions 147 129 +14.0%
Increased positions 1013 933 +8.6%
Reduced positions 911 994 -8.4%
13F shares
Current Prev Q Change
Total value 148.84B 155.34B -4.2%
Total shares 1.28B 1.3B -0.8%
Total puts 7.69M 6.2M +23.9%
Total calls 6.86M 6.64M +3.3%
Total put/call ratio 1.1 0.9 +20.0%
Largest owners
Shares Value Change
Vanguard 147.84M $17.14B +0.9%
BLK Blackrock 132.19M $15.32B -1.4%
Capital Research Global Investors 85.82M $9.95B +0.0%
STT State Street 71.75M $8.32B +1.7%
Capital International Investors 55.97M $6.49B +2.6%
MS Morgan Stanley 28.56M $3.31B +4.5%
Massachusetts Financial Services 26.69M $3.09B +0.1%
Geode Capital Management 26.44M $3.05B +1.7%
NTRS Northern Trust 26.09M $3.02B -1.2%
BAC Bank Of America 24.7M $2.86B -0.3%
Largest transactions
Shares Bought/sold Change
GQG Partners 26.25K -12.81M -99.8%
FMR 14.21M -6.2M -30.4%
Amundi Pioneer Asset Management 0 -4.45M EXIT
Amundi 3.69M +3.69M NEW
Vontobel Asset Management 4.36M +3.34M +328.0%
BlueSpruce Investments 4.21M +3.05M +261.2%
Two Sigma Advisers 3.24M +2.83M +684.2%
Wellington Management 20.19M -2.73M -11.9%
AustralianSuper Pty 2.63M +2.23M +560.8%
1832 Asset Management 17.92K -2.19M -99.2%

Financial report summary

?
Management Discussion
  • The increase in Total Net Sales in 2020 reflects volume growth in the Diagnostics and Nutritional Products segments.  In Medical Devices, the impact of COVID-19 on Abbott’s cardiovascular and neuromodulation businesses was partially offset by double-digit volume growth in Diabetes Care.  The increase in Total Net Sales in 2019 reflects volume growth across all of Abbott’s segments.  The price declines related to the Medical Devices segment in 2020 and 2019 primarily reflect DES pricing pressures as a result of market competition in the U.S. and other major markets.
  • A comparison of significant product and product group sales is as follows.  Percent changes are versus the prior year and are based on unrounded numbers.
  • In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: accelerated, aortic, Canada, cancellation, East, exit, extreme, fixed, fully, globally, guidance, high, Middle, Navitor, network, nonrecurrence, projected, recovery, rollout, surgical, TAVI, transcatheter, unchanged, vaccinated, virtually
Removed: February, Greater, hospital, infant, spread, strong